| Aclarubicin-associated QTc prolongation and ventricular fibrillation. | |
| | |
MedLine Citation:
|
PMID: 6584207 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A marked prolongation of QTc (corrected QT interval for heart rate) in ECG developed in two patients with acute leukemia during induction chemotherapy with aclarubicin, one of the anthracycline antibiotics. This ECG change was followed by ventricular fibrillation. No signs or symptoms of congestive heart failure were noted. The outcome in one case was fatal; in the other case, the ECG change was reversible. These observations suggest that QTc prolongation, which has been considered to be a sign of acute cardiotoxicity of anthracycline derivatives, may signal a clinical risk of ventricular fibrillation. |
| | |
Authors:
|
N Iwata; M Karasawa; M Omine; T Maekawa; T Suzuki; Y Kawai |
Related Documents
:
|
3655597 - Ventricular fibrillation during coronary angiography: the precatheterization qt interval. 15460667 - Effect of different sources of ventricular repolarization heterogeneity on the resultan... 498597 - Electrophysiological and haemodynamic effects of a new inotropic agent (uk14275) in the... 3436147 - Pacemaker therapy for the treatment of the long qt syndrome associated with long-lastin... 9127397 - Right ventricular disarticulation procedures: the role of late potentials in the genesi... 21371317 - Spontaneous coronary artery dissection in a young man - case report. |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer treatment reports Volume: 68 ISSN: 0361-5960 ISO Abbreviation: Cancer Treat Rep Publication Date: 1984 Mar |
Date Detail:
|
Created Date: 1984-05-03 Completed Date: 1984-05-03 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7607107 Medline TA: Cancer Treat Rep Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 527-9 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aclarubicin Adolescent Adult Antibiotics, Antineoplastic Electrocardiography Female Heart Rate / drug effects* Humans Leukemia, Erythroblastic, Acute / drug therapy* Leukemia, Myeloid, Acute / drug therapy* Male Naphthacenes / adverse effects, therapeutic use Ventricular Fibrillation / chemically induced* |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Naphthacenes; 57576-44-0/Aclarubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by ...
Next Document: Responses of isolated dog arteries to amrinone.